Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 97.2 mg; valsartan, quantity: 102.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; purified talc; microcrystalline cellulose; colloidal anhydrous silica; hyprolose; sodium starch glycollate type a; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 48.6 mg; valsartan, quantity: 51.4 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - sacubitril, quantity: 24.3 mg; valsartan, quantity: 25.7 mg - tablet, film coated - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; magnesium stearate; purified talc; colloidal anhydrous silica; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - sacubitril (unii: 17erj0mkgi) (sacubitrilat - unii:spi5pbf81s), valsartan (unii: 80m03yxj7i) (valsartan - unii:80m03yxj7i) - sacubitril 24 mg - entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. benefits are most clearly evident in patients with left ventricular ejection fraction (lvef) below normal. lvef is a variable measure, so use clinical judgment in deciding whom to treat [see clinical studies (14.1)] . entresto is indicated for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. entresto reduces nt-probnp and is expected to improve cardiovascular outcomes. entresto is contraindicated: - in patients with hypersensitivity to any component - in patients with a history of angioedema related to previous ace inhibitor or arb therapy [see warnings and precautions (5.2)] - with concomitant use of ace inhibitors. do not administer within 36 hours of switching from or to an ace inhibitor [see drug interactions (7.1)] - with concomitant use of aliskiren in patients with diabetes [see drug interactions (7.1)] risk summary entresto can cause fetal harm when administered to a pregnant woman. use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. in animal reproduction studies, entresto treatment during organogenesis resulted in increased embryo-fetal lethality in rats and rabbits and teratogenicity in rabbits. when pregnancy is detected, consider alternative drug treatment and discontinue entresto. however, if there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system, and if the drug is considered lifesaving for the mother, advise a pregnant woman of the potential risk to the fetus. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations fetal/neonatal adverse reactions oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death. perform serial ultrasound examinations to assess the intra-amniotic environment. fetal testing may be appropriate, based on the week of gestation. patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. if oligohydramnios is observed, consider alternative drug treatment. closely observe neonates with histories of in utero exposure to entresto for hypotension, oliguria, and hyperkalemia. in neonates with a history of in utero exposure to entresto, if oliguria or hypotension occurs, support blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function. data animal data entresto treatment during organogenesis resulted in increased embryo-fetal lethality in rats at doses ≥ 49 mg sacubitril/51 mg valsartan/kg/day (≤ 0.06 [lbq657, the active metabolite] and 0.72 [valsartan]-fold the maximum recommended human dose [mrhd] of 97/103 mg twice-daily on the basis of the area under the plasma drug concentration-time curve [auc]) and rabbits at doses ≥ 5 mg sacubitril/5 mg valsartan/kg/day (2-fold and 0.03-fold the mrhd on the basis of valsartan and lbq657 auc, respectively). entresto is teratogenic based on a low incidence of fetal hydrocephaly, associated with maternally toxic doses, which was observed in rabbits at an entresto dose of ≥ 5 mg sacubitril/5 mg valsartan/kg/day. the adverse embryo-fetal effects of entresto are attributed to the angiotensin receptor antagonist activity. pre- and postnatal development studies in rats at sacubitril doses up to 750 mg/kg/day (2.2-fold the mrhd on the basis of lbq657 auc) and valsartan at doses up to 600 mg/kg/day (0.86-fold the mrhd on the basis of auc) indicate that treatment with entresto during organogenesis, gestation and lactation may affect pup development and survival. risk summary there is no information regarding the presence of sacubitril/valsartan in human milk, the effects on the breastfed infant, or the effects on milk production. sacubitril/valsartan is present in rat milk. because of the potential for serious adverse reactions in breastfed infants from exposure to sacubitril/valsartan, advise a nursing woman that breastfeeding is not recommended during treatment with entresto. data following an oral dose (15 mg sacubitril/15 mg valsartan/kg) of [14 c] entresto to lactating rats, transfer of lbq657 into milk was observed. after a single oral administration of 3 mg/kg [14 c] valsartan to lactating rats, transfer of valsartan into milk was observed. the safety and effectiveness of entresto in pediatric heart failure patients 1 to < 18 years old are supported by the reduction from baseline to 12 weeks in nt-probnp in a randomized, double-blind clinical study [see clinical studies (14.2)] . the analysis of nt-probnp included 90 patients age 6 to 18 years and 20 patients age 1 to 6 years. safety and effectiveness have not been established in pediatric patients less than 1 year of age. animal data sacubitril given orally to juvenile rats from postnatal day (pnd) 7 to pnd 35 or pnd 70 (an age approximately equivalent to neonatal through pre-pubertal development or adulthood in humans) at doses ≥ 400 mg/kg/day (approximately 2-fold the auc exposure to the active metabolite of sacubitril, lbq657, at an entresto pediatric clinical dose of 3.1 mg/kg twice daily) resulted in decreases in body weight, bone length, and bone mass. the decrease in body weight was transient from pnd 10 to pnd 20 and the effects for most bone parameters were reversible after treatment stopped. exposure at the no-observed-adverse-effect-level (noael) of 100 mg/kg/day was approximately 0.5-fold the auc exposure to lbq657 at the 3.1 mg/kg twice daily dose of entresto. the mechanism underlying bone effects in rats and the translatability to pediatric patients are unknown. valsartan given orally to juvenile rats from pnd 7 to pnd 70 (an age approximately equivalent to neonatal through adulthood in humans) produced persistent, irreversible kidney damage at all dose levels. exposure at the lowest tested dose of 1 mg/kg/day was approximately 0.2-fold the exposure at 3.1 mg/kg twice daily dose of entresto based on auc. these kidney effects in neonatal rats represent expected exaggerated pharmacological effects that are observed if rats are treated during the first 13 days of life. no relevant pharmacokinetic differences have been observed in elderly (≥ 65 years) or very elderly (≥ 75 years) patients compared to the overall population [see clinical pharmacology (12.3)] . no dose adjustment is required when administering entresto to patients with mild hepatic impairment (child-pugh a classification). the recommended starting dose in patients with moderate hepatic impairment (child-pugh b classification) is 24/26 mg twice daily. the use of entresto in patients with severe hepatic impairment (child-pugh c classification) is not recommended, as no studies have been conducted in these patients [see dosage and administration (2.6), clinical pharmacology (12.3)] . no dose adjustment is required in patients with mild (egfr 60 to 90 ml/min/1.73 m2 ) to moderate (egfr 30 to 60 ml/min/1.73 m2 ) renal impairment. the recommended starting dose in patients with severe renal impairment (egfr < 30 ml/min/1.73 m2 ) is 24/26 mg twice daily [see dosage and administration (2.5), warnings and precautions (5.4), and clinical pharmacology (12.3)] .

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: purified talc; colloidal anhydrous silica; crospovidone; titanium dioxide; hypromellose; hyprolose; macrogol 4000; magnesium stearate; iron oxide red; microcrystalline cellulose; iron oxide yellow - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; iron oxide red; titanium dioxide; macrogol 4000; hypromellose; hyprolose; magnesium stearate; microcrystalline cellulose; iron oxide black; purified talc - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - valsartan, quantity: 102.8 mg; sacubitril, quantity: 97.2 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide black; magnesium stearate; titanium dioxide; iron oxide red; purified talc; crospovidone; hypromellose; macrogol 4000; hyprolose; microcrystalline cellulose - entresto is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 51.4 mg; sacubitril, quantity: 48.6 mg - tablet, film coated - excipient ingredients: hyprolose; sodium starch glycollate type a; colloidal anhydrous silica; microcrystalline cellulose; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 4000 - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - valsartan, quantity: 25.7 mg; sacubitril, quantity: 24.3 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; sodium starch glycollate type a; purified talc; microcrystalline cellulose; magnesium stearate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 4000; iron oxide black - pharmacor sacubitril/valsartan is indicated in adult patients for the treatment of chronic heart failure (nyha class ii-iv) with reduced ejection fraction.